SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from BNB PLUS CORP. (BNBX) (CIK 0000744452) (BNBX) — May 24, 2017

BNB PLUS CORP. (BNBX) (CIK 0000744452)
Date: May 24, 2017 · CIK: 0000744452 · Accession: 0001571049-17-005344

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-218158

Date
May 24, 2017
Author
Not clearly detected
Form
CORRESP
Company
BNB PLUS CORP. (BNBX) (CIK 0000744452)

Letter

Applied DNA Sciences, Inc.

50 Health Sciences Drive

Stony Brook, New York 11790

May 24, 2017

VIA EDGAR

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Re: Applied DNA Sciences, Inc.

Registration Statement on Form S-3

Filed May 22, 2017

File No. 333-218158

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Applied DNA Sciences, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-218158) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 3:00 PM, eastern time, on May 26, 2017, or as soon as thereafter as is practicable.

In connection with this request, we acknowledge to the Securities and Exchange Commission (the “Commission”) that:

· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Please feel free to direct any questions or comments concerning this request to Merrill M. Kraines, Esq. of Pepper Hamilton LLP at (212) 808-2711.

APPLIED DNA SCIENCES, INC.

By: /s/ Beth Jantzen

Name: Beth Jantzen

Title: Chief Financial Officer

Show Raw Text
CORRESP
1
filename1.htm

    Applied DNA Sciences, Inc.

    50 Health Sciences Drive

    Stony Brook, New York 11790

    May 24, 2017

VIA EDGAR

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

    Re:
    Applied DNA Sciences, Inc.

    Registration Statement on Form S-3

    Filed May 22, 2017

    File No. 333-218158

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities
Act of 1933, as amended, Applied DNA Sciences, Inc. (the “Company”) hereby requests that the effective date
of the Company’s Registration Statement on Form S-3 (File No. 333-218158) (the “Registration Statement”)
be accelerated so that the Company’s Registration Statement will become effective at 3:00 PM, eastern time, on May 26, 2017,
or as soon as thereafter as is practicable.

In connection with this request, we acknowledge
to the Securities and Exchange Commission (the “Commission”) that:

 · should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose
the Commission from taking any action with respect to the filing;

 · the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does
not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

 · the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by
the Commission or any person under the federal securities laws of the United States.

Please feel free to direct any questions
or comments concerning this request to Merrill M. Kraines, Esq. of Pepper Hamilton LLP at (212) 808-2711.

    APPLIED DNA SCIENCES, INC.

    By:
    /s/	Beth Jantzen

    Name:   Beth Jantzen

    Title:     Chief Financial Officer